You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020202017
Dec 20201703
Jan 20211801
Feb 20212203
Mar 20213204
Apr 20212404
May 2021904
Jun 2021004
Jul 20210012
Aug 2021007
Sep 2021005
Oct 20216023
Nov 202122015
Dec 20211401
Jan 20221603
Feb 20222202
Mar 20224203
Apr 20223405
May 20222500
Jun 20222808
Jul 20221408
Aug 20221804
Sep 20222201
Oct 20221000
Nov 2022401
Dec 20222604
Jan 20231002
Feb 20232201
Mar 2023800
Apr 20231001
May 20231000
Jun 20233205
Jul 2023804
Aug 20232004
Sep 2023400
Oct 20231002
Nov 20232806
Dec 20236000
Jan 20241000
Feb 20244200
Mar 20241801
Apr 20241601
May 20243201
Jun 20245408
Jul 20242804
Aug 20242000
Sep 20241403
Oct 20241007
Nov 20242406
Dec 2024804
Jan 20252608
Feb 2025405
Mar 20250011
Apr 2025004
May 2025005
Jun 2025004
Total11550239